<DOC>
	<DOCNO>NCT02800642</DOCNO>
	<brief_summary>Central retinal vein occlusion ( CRVO ) occur main blood vessel transport blood away retina ( back portion eye ) become block , cause leakage fluid retina thereby cause swell macula ( portion retina responsible fine vision ) . This swell call macular edema . When macula swell fluid , central vision become blurry . The study drug aflibercept show reduce amount fluid blood leak retina . It help stabilize , many case , improve vision loss relate CRVO . Aflibercept approve treatment macular edema secondary CRVO United States ( US ) , European Union ( EU ) , Japan , country . The study consider research , although study drug already market macular edema secondary CRVO , study available address question useful interval treat assess patient , differ among patient , criterion apply retreatment . The purpose study evaluate effectiveness , treatment interval , safety treatment regimen ( pattern administer treatment ) subject macular edema secondary CRVO . In addition , study explore new image method assess affected eye .</brief_summary>
	<brief_title>Evaluation Treat Extend Regimen Intravitreal Aflibercept Macular Edema Secondary CRVO</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Centerinvolved macular edema secondary CRVO longer 3 month ( screen visit ensure subject comply criterion ≤ 3 month since onset macular edema schedule baseline visit ) . Adult subject diagnose macular edema secondary CRVO schedule treat IVT aflibercept per investigator 's routine treatment practice intent use T &amp; E regimen initial dosing . Treatmentnaïve subject macular edema secondary CRVO . Men woman ≥ 18 year age . Documented BCVA ETDRS letter score 73 24 letter ( Snellen equivalent 20/40 20/320 ) study eye . Previous PRP macular laser photocoagulation study eye . Any prior concomitant ocular treatment ( e.g . antiVEGF therapy , corticosteroid ) study eye macular edema secondary RVO , except dietary supplement vitamins prior inclusion study . Intraocular antiVEGF treatment permit treatment disease fellow eye except specifically exclude . Prior systemic antiVEGF corticosteroid therapy , investigational approve , within last 3 month first dose study . Previous use intraocular corticosteroid study eye time use periocular corticosteroid study eye within 12 month prior Day 1 . Any active intraocular , extraocular , periocular inflammation infection either eye within 4 week screen . Any history allergy povidone iodine . Known serious allergy fluorescein sodium injection angiography . Presence contraindication indicate EU commission/locally approve label IVT aflibercept : hypersensitivity active substance IVT aflibercept excipients ; active suspect ocular periocular infection ; active severe intraocular inflammation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Bayer</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Eylea</keyword>
	<keyword>Intravitreal ,</keyword>
</DOC>